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ABSTRACT
Glucagon secretion involves a combination of paracrine, autocrine, hormonal, 
and autonomic neural mechanisms. Type 2 diabetes often presents impaired glucagon 
suppression by insulin and glucose. Insulin-like growth factor-I (IGF-1) has elevated 
homology with insulin, and regulates pancreatic β-cells insulin secretion. Insulin and 
IGF-1 receptors share considerable structure homology and function. We hypothesized 
the existence of a mechanism linking the inhibition of α-cells glucagon secretion to 
IGF-1. Herein, we evaluated the association between plasma IGF-1 and glucagon 
levels in 116 nondiabetic adults. After adjusting for age gender and BMI, fasting 
glucagon levels were positively correlated with 2-h post-load glycaemia, HOMA 
index and fasting insulin, and were negatively correlated with IGF-1 levels. In a 
multivariable regression, the variables independently associated to fasting glucagon 
were circulating IGF-1 levels, HOMA index and BMI, explaining 20.7% variation. 
To unravel the molecular mechanisms beneath IGF-1 and glucagon association, we 
investigated whether IGF-1 directly modulates glucagon expression and secretion 
in an in vitro model of α-cells. Our data showed that IGF-1 inhibits the ability of low 
glucose concentration to stimulate glucagon expression and secretion via activation 
of the phosphatidylinositol-3-kinase/Akt/FoxO1 pathway.
Collectively, our results suggest a new regulatory role of IGF-1 on α-cells 
biological function.
INTRODUCTION
Glucagon is the major hyperglycaemic hormone 
of the body counteracting insulin effects when blood 
glucose falls to dangerously low levels [1]. Glucagon 
secretion by pancreatic α cells is a complex and highly 
regulated process, involving a combination of paracrine, 
autocrine, hormonal, as well as autonomic neural 
mechanisms [2]. Glucagon secretion is mainly regulated 
by insulin and glucose both acting as inhibitors. 
Impaired suppression of glucagon by insulin and glucose 
have been proposed as potential mechanisms for the 
hyperglucagonemia observed in individuals with type 2 
diabetes (T2DM) [3, 4]. Moreover, glucagon suppression 
upon oral glucose challenge is reduced in individuals 
with impaired glucose tolerance (IGT) [5–7]. However, 
in addition to glucose and insulin, glucagon secretion 
is also regulated by both the autonomic nervous system 
and several other hormones and metabolites including 
somatostatin, glucagon-like peptide-1 (GLP-1), amylin, 
leptin, fatty acids - which inhibit glucagon secretion; 
as well as glucose-dependent insulin-tropic peptide 
(GIP), glucagon-like peptide- 2 (GLP-2), amino-
acids such as l-arginine and leucine - which stimulate 
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glucagon secretion. Therefore, it is important to consider 
the complex interplay among metabolic, paracrine, 
autocrine, and hormonal factors when studying glucagon 
secretion in vivo.
Among hormonal factors regulating glucagon 
secretion, the insulin-like growth factor-I (IGF-I) is a 
plausible candidate. IGF-I, which has 48% amino acid 
sequence identity with proinsulin, is the second most 
powerful natural peptide with glucose lowering effects 
after insulin [8], and, in humans, it circulates at relatively 
high concentrations (150–400 ng/ml) [9]. The insulin and 
IGF-1 receptors share considerable homology of structure 
and function including common signalling pathways [10]. 
Lower circulating IGF-1 levels have been associated with 
IGT/T2DM [11–13], and insulin resistance [14, 15]. In 
addition, administration of recombinant IGF-1 increases 
glucose uptake [16, 17], and improves glucose tolerance 
in patients with type 2 diabetes and severe forms of insulin 
resistance [18–20]. By contrast, circulating IGF-1 levels 
are negatively associated with insulin secretion [15]. 
Recombinant human IGF-1 (rhIGF-1) infusion in normal 
subjects reduces insulin secretion while enhancing glucose 
disposal [21, 22], and IGF-1 exhibits inhibitory effects on 
glucose-induced insulin secretion in pancreatic β-cells and 
perfused rat pancreas [23].
However, the role of IGF-1 concentrations on 
glucagon secretion is less clear. The crosstalk between 
IGF-1 and glucagon has seldom been addressed in the 
literature; indeed, in the early 1990s, acute intravenous 
infusions of rhIGF-1 in healthy volunteers were reported 
to impair glucagon excretion and delay recovery after 
IGF-1-induced hypoglycaemia [17, 24]. Since then, no one 
else has attempted to verify the existence of an association 
between these two pivotal hormones and how IGF-1 might 
affect glucagon secretion in vitro.
We hypothesized the existence of a mechanism 
linking the inhibition of glucagon secretion by α-cell 
to IGF-1, as it has been established for β-cell secretion 
[23]. As a consequence, a failure to adequately suppress 
glucagon secretion in response to IGF-1 could contribute 
to hyperglucagonemia observed in prediabetes and T2DM. 
To address this issue, we examined the relationship 
between plasma IGF-1 concentrations and glucagon 
levels in a cohort of nondiabetic adult individuals, and 
tested the hypothesis that IGF-1 directly impairs glucagon 
expression in an in vitro model of pancreatic α-cells.
RESULTS
Cross-sectional analysis
The study cohort consisted of 116 non-diabetic 
subjects of whom 51 were men and 65 were women. 
The clinical characteristics of the whole study group are 
shown in Table 1. The mean age was 38.4 ±11.6 years, and 
mean BMI was 33.5 ± 9.8 kg/m2. Univariate correlations 
between fasting glucagon levels and anthropometric 
and metabolic variables are shown in Table 2. Fasting 
glucagon levels were significantly correlated with age, 
BMI and waist circumference. After adjusting for age 
gender and BMI, fasting glucagon levels were positively 
correlated with 2-h post-load glucose levels, the HOMA 
index of insulin resistance and fasting insulin levels, and 
were negatively correlated with IGF-1 levels (Figure 1 
and Table 2). To estimate whether circulating IGF-1 levels 
were an independent contributor to fasting glucagon levels 
a multivariable regression analysis was performed. We 
found that even when age, gender and BMI, 2-h post-load 
glucose levels, and the HOMA index were included in the 
model, the variables independently associated to fasting 
glucagon levels were circulating IGF-1 levels (β= -0.255, 
P=0.03), HOMA index (β=0.289, P=0.04) and BMI (β= 
-0.267, P=0.05) explaining 20.7% of variation of fasting 
glucagon levels.
These data suggest that circulating IGF-1 may 
reduce glucagon expression/secretion by pancreatic 
α-cells. To address this issue an in vitro model of 
pancreatic α-cells, the α-TC1 clone 6, has been used for 
further experiments.
Effects of IGF-1 on preproglucagon mRNA 
expression
Initially, we wished to confirm the presence of 
the IGF-1 receptor (IGF-1R) in α-TC1 cells. The cells 
were cultured for 24 h in medium containing 24mM of 
glucose before stimulation with low glucose concentration 
(2mM) for 1 h. As shown in Figure 2, the IGF-1R was 
expressed in α-TC1 cells both in the basal state and upon 
low glucose concentration, as determined by Real-Time 
RT-PCR (Figure 2A) and Western blot (Figure 2B). Next, 
we evaluated the effect of IGF-1 on glucagon mRNA 
expression. The α-TC1 cells were incubated in absence 
or presence of increasing IGF-1 concentrations (5, 10, 50, 
100nM) in a medium containing 24mM glucose and then 
were stimulated for 1 h in the presence of 2mM glucose. 
As shown in Figure 3, IGF-1 treatment significantly 
reduced preproglucagon mRNA expression induced by 
low glucose concentration in a dose-dependent fashion, 
with maximal effect occurring at 100nM (P<0.01).
Effects of IGF-1 on the phosphatidylinositol-3-
kinase/Akt/FoxO1 signalling cascade
There is evidence that insulin inhibits the 
preproglucagon gene expression by activating the 
phosphatidylinositol 3-kinase (PI3K)-Akt-Forkhead/
winged helix box gene, group O-1 (FoxO1) signaling 
cascade, resulting in reduced glucagon secretion by 
α-TC1–9 cells [28]. Because insulin and IGF-1 share 
many transduction pathways including the PI3K/Akt/
FoxO1 signalling cascade, we wished to inquire whether 
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IGF-1 affected this signalling pathway in α-TC1-6. 
To test this hypothesis, α-TC1 cells incubated at low 
glucose condition (2 mM) were exposed to increasing 
concentration of IGF-1. Lysates from these IGF-1-treated 
α-TC1 cells were immunoblotted with anti-phospho-
Akt (Ser473) and anti-FoxO1 (Thr24) antibody. IGF-1 
increased Ser473 Akt phosphorylation 2.0-fold (basal 
levels vs. levels in cells stimulated with 100 nM IGF-1; 
P<0.01) (Figure 4A) and Thr24 FoxO1 phosphorylation 
1.8-fold (basal levels vs. levels in cells stimulated with 
100nM IGF-1; P<0.01) (Figure 4B). The PI3K inhibitor 
LY294002 is largely used to verify the effects of PI3K 
on downstream kinases, such as Akt, without affecting 
tyrosine phosphorylation of both the insulin/IGF-1 
receptor beta-subunits and insulin receptor substrate 1 
(IRS-1), or the association of the p85 regulatory subunit 
Table 2: Univariate correlations between fasting glucagon levels and anthropometric and biochemical variables
Age, gender, and BMI adjusted
correlations between fasting glucagon levels and metabolic variables P
Pearson’s correlation coefficient (r)
Age (yrs) -0.19 0.003*
BMI (kg/m2) 0.14 0.05§
Waist circumference (cm) 0.14 0.05§
Systolic blood pressure (mmHg) 0.08 0.19
Diastolic blood pressure (mmHg) 0.01 0.48
HbA1c (%) 0.05 0.49
IGF-1 (ng/ml) -0.17 0.03
Fasting Glucose (mg/dl) 0.04 0.40
2-h glucose (mg/dl) 0.18 0.03
Fasting plasma Insulin (μU/ml) 0.14 0.05
HOMA index 0.17 0.03
BMI = Body mass index; *P values refer to results after analyses with adjustment for gender. §P values refer to results after 
analyses with adjustment for age and gender.
Table 1: Clinical and biochemical characteristics of study subjects
Clinical characteristic Mean (± SD)
Gender [male/female] 51/65
Age (yrs) 38.4 ± 11.6
BMI (kg/m2) 33.5 ± 9.8
Waist circumference (cm) 109.4 ± 21.6
Systolic blood pressure (mmHg) 122.1 ± 15.9
Diastolic blood pressure (mmHg) 77.6 ± 12.1
HbA1c [%] (mmol/mol) 5.4 ± 0.6 [36]
IGF-1 (ng/ml) 173.5 ± 53.9
Fasting plasma glucose (mg/dl) 90 ± 11
2-h glucose (mg/dl) 123 ± 43
Fasting plasma insulin (μU/ml) 16.5 ± 11.0
Fasting glucagon (pg/ml) 47.7 ± 13.6
Matsuda index 64 ± 50
Data are means ± SD.
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of PI3K with IRS-1 [29]. To determine whether the 
alterations observed in Akt and FoxO1 phosphorylation 
were dependent on PI3K activation, α-TC1 cells were 
pre-treated with LY294002 (40 μM), then the lysates were 
immunoprecipitated with IRS-1 antibody and blotted 
for p85. As reported in Figure 4C, pre-treatment with 
LY294002 (40 μM) markedly reduced IGF-1 stimulated 
Akt and FoxO1 phosphorylation, (Figure 4A and 4B, 
respectively). Accordingly, the inhibitory effects of IGF-
Figure 1: Inverse relationship between fasting glucagon and IGF-1 levels.
Figure 2: Expression of IGF-1R in α-TC1 clone 6 cultured for 24 h in DMEM under high glucose (24 mM) and low 
glucose (2mM) condition. (A) The image shows Real Time RT-PCR detection of IGF-1 mRNA levels in αTC1 cells (B) Western blot 
analysis for p-IGF-1R and β-tubulin. Shown is a representative experiment for IGF-1R in α-TC1 cells.
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1 on preproglucagon mRNA expression were abolished 
when α-TC1 cells were exposed to LY294002 (Figure 4D).
We next used the Akt inhibitor VIII (AKTi VIII), 
a specific inhibitor of Akt, to further explore the role 
of Akt signalling pathway in mediating the inhibitory 
effect of IGF-1 on glucagon expression. To this aim, 
α-TC1 cells were pre-treated with AKTi VIII (210 
nM), and subsequently exposed to IGF-1 (100nM), and 
stimulated with hypoglycemic culture medium (2mM 
glucose). The stimulatory effects of IGF-1 on Akt and 
FoxO1 phosphorylation were abolished by pre-incubation 
of α-TC1 cells with AKTi VIII (Figure 5A and 5B, 
respectively). Accordingly, the inhibitory effects of IGF-
1 on preproglucagon mRNA expression were abrogated 
when α-TC1 cells were exposed to AKTi VIII (Figure 5C). 
Taken together, these results suggest that IGF-1 negatively 
modulates glucagon expression by activating the PI3K/
Akt/FoxO1 signalling cascade.
Figure 3: Dose-response effect of IGF-1 on preproglucagon mRNA levels, p-Akt (Ser473) and FOXO1 (Thr24) 
phosphorylation. α-TC1 cells were incubated in presence of increasing IGF-1 concentrations (5, 10, 50, 100nM). (A) Preproglucagon 
mRNA level was measures by Real Time RT-PCR. (B) Representative western blot images of p-Akt (Ser473), total Akt and β-tubulin. 
(C) Representative western blot images of p-FOXO1 (Thr24), total FOXO1 and β-tubulin. Data are means ± SD of three independent 
experiments, each done in triplicate. *P<0.01 and #P<0.05 vs. 24mM, ##P<0.01 and **P=0.02 vs. 2mM.
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Figure 4: Effect of IGF-1 on PI3K/Akt pathway and preproglucagon mRNA levels. α-TC1 cells were cultured with IGF-
1 100nM in presence or absence of PI3K inhibitor LY294002. (A) Representative western blot images of p-Akt (Ser 473), total Akt 
and β-tubulin. (B) Representative western blot images of p-FoxO1 (Thr24), total FoxO1 and β-tubulin. (C) Representative Western blot 
images for p85 and total IRS-1. (D) Preproglucagon mRNA level measured by Real Time RT-PCR. Data are means ± SD of 4 independent 
experiments, *P<0.02 and ##P<0.01 vs 24mM, **P≤0.01 and %P=0.01 vs. 2mM, #P<0.01 and %%P=0.02 vs. IGF-1.
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Effects of IGF-1 on glucagon secretion induced 
by low glucose concentration
To evaluate the effects of IGF-1 on glucagon 
secretion, α-TC1 cells were exposed to IGF-1 (100nM) in 
medium containing 24mM glucose, and then stimulated 
with low glucose concentration (2mM) for 1 h. Culture 
media were collected and glucagon concentrations were 
assayed by ELISA kit. Low glucose stimulated glucagon 
secretion by 80% over basal (Figure 6). Treatment with 
IGF-1 completely abolished the stimulatory effects of low 
glucose concentrations. The inhibitory effects of IGF-1 
were abrogated when α-TC1 cells were pre-treated with 
AKTi VIII or LY294002 inhibitors (Figure 6A and 6B, 
respectively).
Figure 5: Inhibition of glucagon synthesis and preproglucagon mRNA levels by IGF-1 is Akt pathway-dependent. 
α-TC1 cells were cultured with IGF1 100nM in presence or absence of Akt inhibitor VIII. (A) Representative western blot images of 
p-Akt (Ser473), total Akt and β-tubulin. (B) Representative western blot images of p-FoxO1 (Thr24), total FoxO1 and β-tubulin. (C) The 
preproglucagon mRNA level was measured by Real Time RT-PCR. Data are means ± SD of 4 independent experiments, #P<0.02 vs. 24mM, 
*P< 0.01 vs. 2mM, ##p<0.02 and **P<0.01 vs. IGF-1.
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DISCUSSION
Glucagon is the paradigm of catabolic hormones, 
it counteracts insulin action in hypoglycaemic conditions 
[30], via the stimulation of gluconeogenesis and 
glycogenolysis in the liver [31] thus playing an important 
role in glucose homeostasis in both normo- and hypo-
glycemic conditions. Glucagon secretion is regulated by 
the fine interaction of several elements, including glucose, 
insulin, incretin hormones, somatostatin, amino-acids, 
and fatty acids [31–34]. IGF-1, instead, enhances insulin 
metabolic and anabolic action, and lower IGF-1 levels 
have been shown to associate with impaired glucose 
tolerance, insulin resistance and metabolic syndrome, and 
to predict T2DM onset [15, 35–37]. The disregulation of 
both hormones has been suggested to contribute to the 
etiopathogenesis of T2DM [11, 35, 38, 38, 7].
Figure 6: High IGF-1 concentrations inhibit glucagon secretion. Histograms represent glucagon measured in the supernatants. 
α-TC1 cells were incubated in DMEM under high glucose (24 mM) in presence or absence of IGF-1 (100nM) and (A) Akt inhibitor VIII 
or (B) PI3K inhibitor LY294002. The cells were then stimulated for 1 h with low glucose (2 mM), and glucagon was measured in the 
supernatant and normalized for total protein amount. Data are means ± SD, of 4 experiments in triplicate, #P<0.03 vs. 24mM,*P<0.02 vs. 
2mM; **P<0.03 vs. IGF-1.
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IGF-1 is structurally and functionally similar to 
insulin; through the binding of its receptor (IGF-1R), 
IGF-1 triggers the activation of the PI3K/Akt signalling 
cascade, which is common to the insulin receptor 
signalling [39]. Convincing evidence has demonstrated 
that insulin signalling is an important regulator of 
glucagon secretion as demonstrated by studies in cellular 
and animal models [28, 40–42]. However, the role of IGF-
1 and its signalling in modulating glucagon expression 
and secretion has been investigated in few reports from 
the 1990s. These early studies were designed to assay the 
immediate effects of exogenous administration of rhIGF-1 
in small numbers of healthy or diabetic patients. Most of 
them observed a decrease in glucagon levels at different 
concentrations of IGF-1, despite two studies reported 
that basal and stimulated glucagon secretion remained 
unchanged [8, 43, 17, 16, 24, 44]. One molecular study 
from 1988 observed that glucagon release was not affected 
by exogenous IGF-1 in human foetal islet-like cell clusters 
[45]. The inconsistencies of the study designs and the 
small number of subjects employed for in vivo tests has 
not allowed for the hypothesis of a cross-talk between 
the two hormones to be resolved, yet. These observations 
coupled with the accessibility of a carefully characterized 
cohort of nondiabetic adult individuals have provided the 
rationale for examining the existence of a mechanism 
linking inhibition of glucagon secretion by α-cell to IGF-1. 
Here, we report an inverse relationship between circulating 
IGF-1 and fasting glucagon levels consistent with the pilot 
experimental data showing that rhIGF-1 acutely decreases 
glucagon concentration [22, 23]. Importantly, the inverse 
relationship remains significant after adjustment for 
several confounders potentially affecting either circulating 
IGF-1 or fasting glucagon levels, including age, gender, 
adiposity [13], insulin sensitivity [3, 15], dyslipidemia 
[14] and glucose tolerance status [46, 47].
The view that circulating IGF-1 is a bona fide 
modulator of glucagon secretion is supported by our in 
vitro findings in α-TC1 clone 6 cells, a mouse model of 
pancreatic α-cells that maintains the capability to secrete 
glucagon in response to low glucose concentrations. We 
found, for the first time, that IGF-1 dose-dependently 
inhibited preproglucagon expression stimulated by low 
glucose concentration. More importantly, these results 
were already observed when using physiological IGF-1 
concentrations (10 nM, or 76.3 ng/ml), thus suggesting 
that present findings may be clinically relevant. 
Additionally, we show that exposure of α-TC1 cells 
to IGF-1 stimulates PI3K/Akt signaling, which is the 
canonical pathway involved in the transduction of IGF-1 
action. It has been reportedly demonstrated that FoxO1 
is expressed in mature primary α-cells, in which it binds 
directly to an upstream region within the preproglucagon 
gene promoter whose elimination or mutation abolishes 
transcriptional regulation by insulin [28, 48]. FoxO1 
activity is regulated via its phosphorylation by Akt. 
When cells are exposed to insulin or other stimulators 
of the PI3K/Akt pathway, FoxO1 is phosphorylated at 
least at three Akt consensus sites, Thr-24, Ser-256, Ser-
319. FoxO1 phosphorylation at Thr-24 results in its 
nuclear export and cytoplasmic sequestration through 
interaction with 14-3-3 proteins. Under conditions of 
deprivation of insulin or other stimulators of the PI3K/
Akt pathway, FoxO1 is not phosphorylated at the Akt 
sites, and accumulates in the nucleus where it can activate 
genes transcription. Accordingly, we found that IGF-1 
induces the phosphorylation of FoxO1 at the Thr-24 site 
via the PI3K/Akt pathway thus preventing the activation 
of preproglucagon synthesis. We support this scenario by 
demonstrating the cause-and-effect relationship between 
these two events through the inhibition of PI3K and Akt 
using specific chemical inhibitors of these two kinases: 
both inhibitors abrogate the stimulatory effects of IGF-
1 on Akt and FoxO1 preventing the inhibitory effect 
of IGF-1 on preproglucagon expression and secretion 
second to low glucose concentration. It is possible to 
exclude the involvement of cross-interactions with the 
insulin receptor, because previous studies performed on 
murine 3T3 fibroblasts transfected with and expressing 
homotypic insulin receptors have shown that IGF-1 at 
the concentration of 100 nM interacts poorly with the 
insulin receptors and its signal transduction is exclusively 
mediated by the IGF-1R [49]. However, we cannot 
exclude that IGF-1 was acting through insulin/IGF-1 
hybrid receptors that bind IGF-1, but not insulin, with high 
affinity [50, 51]. Together these data implicate PI3K/Akt/
FoxO1 pathway as an important mediator of the effects 
of IGF-1 on preproglucagon gene expression and IGF-1 
as a bona fide regulator of glucagon secretion. Obviously, 
we cannot exclude the possibility that other molecular 
mechanisms might mediate the inhibitory effect of IGF-
1 on preproglucagon expression and secretion such as 
Akt-induced recruitment of the gamma-aminobutyric acid 
(GABA)-A receptor to the cellular membrane resulting 
in GABA inhibition of glucagon secretion [52]. Further 
studies are needed to clarify this issue.
The present study has several strengths including 
a larger sample size than those used in prior studies 
including both men and women, the measurements of 
metabolites and hormones in fresh blood samples rather 
than in stored samples that may lead to their degradation, 
and the centralization of biochemical assays, the exclusion 
of confounding conditions affecting both IGF-1 and 
glucagon levels, and the combination of in vivo and in 
vitro approaches to assess the relationship between IGF-1 
and glucagon.
Nevertheless, the current study has potential 
limitations. First, IGF-1 and glucagon circulating levels 
were measured once, a common approach in clinical 
practice, and small variations in these variables would 
therefore be expected if the same assays were repeated 
on a different day. Second, free IGF-1 levels were not 
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measured, and this should be considered as another 
limitation of the study. Moreover, in contrast with prior 
reports, we did not assess the acute effect of exogenous 
IGF-1 infusion on glucagon levels, and due to the 
cross-sectional design of the study, the present findings 
reflect only an association between circulating IGF-1 
levels and fasting glucagon concentration, therefore no 
definitive cause and effect relationship can be inferred. 
Furthermore, the present study is based on outpatients 
recruited at a referral university hospital, representing 
individuals at enhanced risk for metabolic disease, and, 
therefore, may not be extendible to the general population. 
Additionally, our results are only based on White 
Europeans, and could not be extended to other ethnic 
groups. Finally, we are aware that for the assessment of 
α-cell function experiments in primary cells from human 
donors or animals would be the best option This ideal 
material, though, is quite rare and there is high risk of 
contamination with neighbouring β-cells. To overcome 
this issue, we have chosen to use the clone 6 derived 
from α-TC1 cells, which is terminally differentiated, 
does not express insulin, and produces glucagon in 
response to the hypoglycemic stimulus [53, 54]. As a 
safety measure in our studies we made sure to include two 
experimental points of basal alphaTC1-6 cells at 24 mM 
and 2 mM glucose concentration, in each experiment, so 
that we could be sure that the cells were physiologically 
responding to the hypoglycemic stimulus.
In summary, we provide in vivo and in vitro 
evidence for a role for IGF-1 signalling in the regulation 
of glucagon secretion by pancreatic α-cells. We propose 
that IGF-1 contributes to modulate glucagon secretion as 
in vivo findings recapitulate our in vitro results showing 
that IGF-1 inhibits the ability of low glucose concentration 
to stimulate glucagon expression and secretion via a 
mechanism involving activation of the PI3K/Akt/FoxO1 
pathway. However, further studies are needed to clarify the 
inhibitory effects of IGF-1 on glucagon secretion in vivo, 
since its regulation is complex due to the combined effects 
of several hormones and metabolites.
MATERIALS AND METHODS
Study population
The study group consisted of 116 adult Caucasian 
subjects (age range 18-65) participating in the CAtanzaro 
MEtabolic RIsk factors (CATAMERI) study, an 
observational study assessing cardio-metabolic risk 
factors in individuals carrying at least one risk factor 
including overweight/obesity, hypertension, dyslipidemia, 
dysglycemia and family history for T2DM [25, 26].
Exclusion criteria were presence of end stage renal 
disease, chronic gastrointestinal diseases associated 
with malabsorption, chronic pancreatitis, history of any 
malignant disease, self-reporting alcohol consumption >20 
g/day, positivity for antibodies to hepatitis C virus (HCV) 
or hepatitis B surface antigen (HBsAg), and therapy 
with drugs known to influence glucose tolerance (e.g. 
steroids, beta-blockers, and thiazide diuretics). Approval 
was obtained from the local ethics committee (Comitato 
Etico Azienda Ospedaliera “Mater Domini”) and written 
informed consent was obtained from each subject before 
commencing the studies in accordance with the principles 
of the Declaration of Helsinki.
Measurements and analytical determinations
Subjects underwent anthropometrical evaluation 
and venous blood samples were drawn in the morning, 
after an overnight fast, using vacutainer tubes for 
laboratory determinations. Height (m) was measured to 
the closest centimetre, weight (kg) to the closest g, and 
BMI was calculated as the ratio of weight in kg to the 
square of height in m. Waist circumference was taken at 
umbilical level to the closest centimetre. Blood pressure 
was measured using a standard sphygmomanometer in 
the sitting position, as the average of the last two of three 
consecutive measurements obtained at 3 min intervals. 
After a 12-h fast, a 75-g OGTT was performed with 0, 30, 
60, 90 and 120 min sampling for plasma glucose.
Glucose, triglycerides, total and high density 
lipoprotein (HDL) cholesterol concentrations were 
determined by enzymatic methods (Roche, Basel, 
Switzerland). Glucagon was measured using a 
radioimmunoassay kit (Millipore Corporation, Billerica, 
MA, USA). Plasma insulin concentration was measured 
with a chemiluminescence-based assay (Immulite®, 
Siemens Healthcare GmbH, Erlangen, Germany), and 
total serum IGF-1 was assayed by one-step sandwich 
chemiluminescence immunoassay (CLIA) after prior 
separation of IGF-1 from binding proteins on the Liaison® 
autoanalyzer (DiaSorin, Saluggia, Italy).
α-TC1 clone 6 cells and culture conditions
Pancreatic α-TC1 clone 6 cell line (ATCC, 
Middlesex, UK) were grown in DMEM with L-glutamine 
(modified to contain 16.7 mmol/L glucose and 1.5 g/L 
sodium bicarbonate) supplemented with 10% (vol/
vol) inactivated foetal calf serum and 1% (vol/vol) 
antibiotics-antimycotics, 15 mmol/L HEPES, 0.1 mmol/L 
nonessential amino acids, and 0.02% BSA, and maintained 
in a humidified atmosphere of 5% CO2 in air at 37°C. 
Cells were subcultured once a week and the medium was 
replaced at least twice weekly. α-TC1 cells were treated 
with IGF-1 (5, 10, 50 or 100nM) for 24 h, Akt inhibitor 
VIII (210nM) for 2 h and/or phosphatidylinositol-3-
kinase (PI3K) inhibitor LY294002 (40μM) for 30 min, 
as indicated. For glucagon secretion determinations, 
supernatants were collected from α-TC1 cells and 
glucagon secretion was measured using the Glucagon 
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Quantikine ELISA Kit (R&D Systems Europe, Lille, 
France) according to the manufacturer's instructions. 
For normalization purposes, total protein amount 
was determined with the Bradford assay (DC Protein 
Assay; Bio-Rad, Hercules, CA, USA) according to the 
manufacturer’s instructions.
Chemicals and reagents
Media, sera and antibiotics for cell culture were 
from Lonza (Walkersville, MD, USA). Akt inhibitor 
VIII and PI3K inhibitor LY294002 were purchased from 
Calbiochem (Merck KGaA, Darmstadt, Germany). IGF-
1 and all other chemical reagents were obtained from 
Sigma-Aldrich Co. LLC (Wassergasse, Switzerland). The 
antibodies used were: anti-Akt, anti-p-Akt (Ser473), anti-
IRS1, anti-p85, anti-FoxO1, anti-p-FoxO1 (Thr24) (Cell 
Signaling Technology, MA, USA), anti-p-IR/IGF-1R (Tyr 
1158/1162/1163) (Merck KGaA, Darmstadt, Germany), 
anti β-Tubulin (Santa Cruz, CA, USA).
Western blot analysis
α-TC1 (clone 6) protein content was obtained by 
lysing cells in buffer containing 50 mmol/L HEPES (pH 
7.5), 150 mmol/L NaCl, 10 mmol/L EDTA, 1% Triton 
X-100, 10 mmol/L Na4P2O7, 100 mmol/L NaF, and 
2 mmol/L sodium orthovanadate, supplemented with 
a cocktail of protease inhibitors. Protein concentration 
was determined with the Bradford assay (DC Protein 
Assay; Bio-Rad, Hercules, CA, USA) according to the 
manufacturer’s instructions. Equal amounts of proteins 
resolved by SDS-PAGE were electrophoretically 
transferred to nitrocellulose membrane (Amersham 
Biosciences, Piscataway, NJ, USA). The membranes were 
incubated with primary antibodies and visualized using 
appropriate peroxidase-conjugated secondary antibodies 
followed by enhanced chemiluminescence detection 
(Amersham Biosciences, Piscataway, NJ, USA). Band 
densities were quantified by densitometry. To normalize 
the blots for protein levels, membranes were stripped and 
reprobed with anti-IRS-1, anti-Akt or anti-FoxO1 antibody 
after immunoblotting with their respective anti-phospho-
specific antibodies. Akt and FoxO1 phosphorylation was 
calculated as the ratio of phosphorylated to total protein 
expression.
mRNA isolation and quantification by real-time 
PCR
Total RNA was extracted from cells by TRIzol 
reagent (Life Technologies, Gaithersburg, MD, USA), 
according to the manufacturer’s instructions. cDNA 
was reverse transcribed by High-Capacity cDNA 
Reverse Transcription Kit (Invitrogen, Thermo Fisher 
Scientific, Waltham, MA, USA) then analysed with 
TaqMan pre-designed gene-expression assays (Thermo 
Fisher Scientific, Waltham, MA, USA) on iQ5 real-time 
thermocycler (Bio-Rad, Hercules, CA, USA). Results 
were normalized to the geometrical average of the levels 
of two housekeeping genes, Rn18S and RPS9, according 
to the Livak method.
Calculations
Insulin sensitivity was estimated by the HOMA 
index, calculated as previously described [27].
Statistical analysis
Variables with skewed distribution including 
triglycerides, IGF-1, fasting insulin, and HOMA index 
were natural log transformed for statistical analyses. 
Continuous data are expressed as means ± SD. Partial 
correlation coefficients adjusted for age, gender and BMI 
were computed between variables. A multivariable linear 
regression analysis was performed in order to evaluate 
the independent contributions of plasma IGF-1 and other 
metabolic factors to fasting plasma glucagon levels. The 
variance inflection factor (VIF) was less than 2.5 in all the 
analyses indicating that multicollinearity among variables 
was not a problem in the multiple regression models with 
the exception of the HOMA index which showed a VIF 
values higher than 47 when the model included fasting 
glucose and insulin levels. For this reason, the model 
included the HOMA index rather than fasting glucose 
and insulin levels (VIF<2). A two-tailed P value <0.05 
was considered statistically significant. All analyses were 
performed using SPSS (Chicago, IL, USA) software 
programme Version 22.0 for Windows.
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